NetMeds acquires JustDoc for just under a million

NEW DELHI: Online pharmacy Net-Meds has acquired telemedicine portal JustDoc in a cash-and-stock deal, the second acquisition by the Chennai-based company, which had acquired hyperlocal drugs delivery startup Pluss last year.

NetMeds acquires JustDoc for just under a million While the terms of the transaction were not disclosed, Netmeds is believed to have paid a little under $1 million to acquire three-year-old JustDoc, which counts former Infosys senior executive TV Mohandas Pai, InMobi cofounder Mohit Saxena, TaxiForSure cofounder Raghunandan G as its angel investors and Singapore Angel Network and Tracxn Labs among its list of backers. All the investors of JustDoc, who had invested an undisclosed amount in the Bengaluru-based venture, are believed to be exiting the startup, post the closure of the deal.

“We were looking to add diagnostic services, given that our aim is to provide a more holistic health platform to our consumers, particularly those dealing with chronic health issues… Getting into diagnostics and telemedicine was a critical part,” Pradeep Dadha, chief executive of NetMeds, told ET.

This is the second acquisition by NetMeds, which competes with the likes of Sequoia Capital-backed 1mg. The latest buyout, according to Dadha, has been funded from the proceeds of the company’s last equity financing round, which was announced earlier this month.

NetMeds had raised $35 million in its Series-C round, which was led by Singapore-based Daun Penh Cambodia Group, and also saw participation from its existing set of investors, a list that includes Sistema Asia Fund, the venture capital arm of Russian conglomerate Sistema JSFC and Tanncam Investment, a Cambodian investment holding company, according to reports.

  • Related Posts

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Mumbai: Cancer patients and their caretakers in India often spend long, arduous hours in hospitals for conventional treatment. But now with the launch of the world’s first subcutaneous or under-the-skin…

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    New Delhi:  The Central Drugs Standard Control Organization (CDSCO) and state drug regulatory authorities have intensified drug safety crackdown as substandard and spurious medicine cases have risen during the last…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

    Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

    ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

    ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026